Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has ...

The Food and Drug Administration (FDA) is coming under fire for not publicizing its own report into an E. coli outbreak last year that spread across 15 states and infected 89 people, one of whom died.

Despite the severity of the outbreak, the Food and Drug Administration (FDA) never made a public announcement. According to an internal report, the investigation was closed quietly in February ...

today announced that it has continued to expand coverage for Ryoncil ® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand ...

today announced that it has continued to expand coverage for Ryoncil ® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...